Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Story1
OrbiMed-affiliated fund OPI VII reports 12.3% stake in Aspen Neuroscience
A Schedule 13D filed on 6 November 2026 shows OPI VII, a Delaware limited partnership managed by OrbiMed Advisors LLC, holds 3,589,132 shares of Aspen Neuroscience, Inc., equal to approximately 12.3% of the company's outstanding shares.
Company or person22
Carter Peter W
Company
MAY PETER W
Company
Carter Walter E.
Company
Peter A Cox
Person
Cancelmo Peter B
Company
CRIST PETER D
Company
CARTER SUSAN K
Company
Peter Boam
Person
Peter Harf
Person
Feld Peter
Company
MOLL PETER
Company
CARTER DARYL J
Company
Carter Starlett
Company
BIERE PETER
Company
Behner Peter
Company
CARTERS INC
Company
Platzer Peter
Company
Chin Peter Scott
Company
CURRIE PETER L S
Company
Peter R Courtney
Person
ADAMEK PETER
Company
KASH PETER M
Company
Primary record6
Carter Peter W filed 4
SEC form 4 filed by Carter Peter W (CIK 1647706) on 2026-11-06.
Aspen Neuroscience, Inc. filed SCHEDULE 13D
on October 30, 2026. As of the date of this filing, OPI VII, a limited partnership organized under the laws of Delaware, holds 3,589,132 Shares constituting approximately 12.3% of the issued and outstanding Shares. OrbiM
ArriVent BioPharma, Inc. filed SCHEDULE 13D/A
(the "SEC") on February 5, 2024 and amended by Amendment No. 1 thereto filed with the SEC on August 13, 2025. This Amendment No. 2 is being filed to report that as a result of the transactions described in Item 5 below,
Carter Peter W filed 4
SEC form 4 filed by Carter Peter W (CIK 1647706) on 2026-09-30.
Braveheart Bio, Inc. filed SCHEDULE 13D/A
(the "SEC") on August 18, 2026. This Amendment No. 1 is being filed to report that the percentage of outstanding shares of common stock of the Issuer, par value $0.0001 per share ("Shares") that the Reporting Persons may
MBX Biosciences, Inc. filed SCHEDULE 13D/A
(the "SEC") on September 23, 2024 and amended by Amendment No. 1 thereto filed with the SEC on September 30, 2025 and Amendment No. 2 thereto filed with the SEC on February 11, 2026. This Amendment No. 3 is being filed t